A multi-institution team led by Northwestern University advanced implantable “living pharmacy” technology, engineering cells to continuously produce multiple therapies inside the body. Published in Device, the work describes a wireless, fully implantable platform designed to simultaneously generate three biologics—an anti-HIV antibody, a GLP-1-like peptide for type 2 diabetes, and leptin—while maintaining cell viability in vivo. In small animal models, the device supported stable production over weeks by integrating oxygen-generating bioelectronics to address oxygen competition that typically limits encapsulated cell therapies. The platform is positioned as a route to sustained multi-therapy delivery without repeated dosing.